Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Steven P Treon

Showing results (101-110 of 323) with videos related to

Pageof 33
Sort By:
Blood|January 24, 2018
Extracellular vesicle-mediated transfer of constitutively active MyD88<sup>L265P</sup> engages MyD88<sup>wt</sup> and activates signalingMateja Manček-Keber, Duško Lainšček, Mojca Benčina, et al.
American Journal of Hematology|May 15, 2018
Spotting the elusive Siberian tiger: Complete response to ibrutinib in a patient with Waldenström MacroglobulinemiaJorge J Castillo, Toni Dubeau, Amanda Kofides, et al.
Blood Advances|October 21, 2025
Familial Clusters and Clinical Features, Complications, and Outcomes in 1000 Patients with Waldenström MacroglobulinemiaAndres Ramirez-Gamero, Nickolas Tsakmaklis, Zachary R Hunter, et al.
British Journal of Haematology|July 14, 2016
Ibrutinib penetrates the blood brain barrier and shows efficacy in the therapy of Bing Neel syndromeChristopher Mason, Steven Savona, Josephine N Rini, et al.
Biologics : Targets & Therapy|August 27, 2009
Advances in the treatment of monoclonal gammopaties: The emerging role of targeted therapy in plasma cell dyscrasiasAldo M Roccaro, Irene M Ghobrial, Simona Blotta, et al.
British Journal of Haematology|November 9, 2018
Long survival in patients with Waldenström macroglobulinaemia diagnosed at a young ageAmaara Babwah, Joshua Gustine, Kirsten Meid, et al.
Clinical Lymphoma & Myeloma|April 14, 2009
Comparative outcomes following CP-R, CVP-R, and CHOP-R in Waldenström's macroglobulinemiaLeukothea Ioakimidis, Christopher J Patterson, Zachary R Hunter, et al.
Clinical Lymphoma, Myeloma & Leukemia|October 23, 2012
Familial disease predisposition impacts treatment outcome in patients with Waldenström macroglobulinemiaSteven P Treon, Christina Tripsas, Christina Hanzis, et al.
British Journal of Haematology|May 20, 2003
Recombinant humanized anti-CD40 monoclonal antibody triggers autologous antibody-dependent cell-mediated cytotoxicity against multiple myeloma cellsToshiaki Hayashi, Steven P Treon, Teru Hideshima, et al.
British Journal of Haematology|January 10, 2023
Dose reductions in patients with Waldenström macroglobulinaemia treated with ibrutinibShayna Sarosiek, Joshua N Gustine, Catherine A Flynn, et al.
Pageof 33

Showing results (101-110 of 323) with videos related to

Sort By:
Pageof 33
Blood|January 24, 2018
Extracellular vesicle-mediated transfer of constitutively active MyD88<sup>L265P</sup> engages MyD88<sup>wt</sup> and activates signalingMateja Manček-Keber, Duško Lainšček, Mojca Benčina, et al.
American Journal of Hematology|May 15, 2018
Spotting the elusive Siberian tiger: Complete response to ibrutinib in a patient with Waldenström MacroglobulinemiaJorge J Castillo, Toni Dubeau, Amanda Kofides, et al.
Blood Advances|October 21, 2025
Familial Clusters and Clinical Features, Complications, and Outcomes in 1000 Patients with Waldenström MacroglobulinemiaAndres Ramirez-Gamero, Nickolas Tsakmaklis, Zachary R Hunter, et al.
British Journal of Haematology|July 14, 2016
Ibrutinib penetrates the blood brain barrier and shows efficacy in the therapy of Bing Neel syndromeChristopher Mason, Steven Savona, Josephine N Rini, et al.
Biologics : Targets & Therapy|August 27, 2009
Advances in the treatment of monoclonal gammopaties: The emerging role of targeted therapy in plasma cell dyscrasiasAldo M Roccaro, Irene M Ghobrial, Simona Blotta, et al.
British Journal of Haematology|November 9, 2018
Long survival in patients with Waldenström macroglobulinaemia diagnosed at a young ageAmaara Babwah, Joshua Gustine, Kirsten Meid, et al.
Clinical Lymphoma & Myeloma|April 14, 2009
Comparative outcomes following CP-R, CVP-R, and CHOP-R in Waldenström's macroglobulinemiaLeukothea Ioakimidis, Christopher J Patterson, Zachary R Hunter, et al.
Clinical Lymphoma, Myeloma & Leukemia|October 23, 2012
Familial disease predisposition impacts treatment outcome in patients with Waldenström macroglobulinemiaSteven P Treon, Christina Tripsas, Christina Hanzis, et al.
British Journal of Haematology|May 20, 2003
Recombinant humanized anti-CD40 monoclonal antibody triggers autologous antibody-dependent cell-mediated cytotoxicity against multiple myeloma cellsToshiaki Hayashi, Steven P Treon, Teru Hideshima, et al.
British Journal of Haematology|January 10, 2023
Dose reductions in patients with Waldenström macroglobulinaemia treated with ibrutinibShayna Sarosiek, Joshua N Gustine, Catherine A Flynn, et al.
Pageof 33